Key facts
- International consensus on CJD biomarkers and criteria with authors from Goettingen (Zerr, Hermann), NPDPSC, RML, Edinburgh (Green), UCSF (Geschwind), Melbourne (Collins), Vienna/Toronto (Kovacs), UCL (Mead) and CIBERNED Spain; RT-QuIC accepted into diagnostic criteria.
- Edinburgh (Green, Pal) with Goettingen (Hermann, Zerr) and others: concordance work for CSF RT-QuIC across European national surveillance laboratories.
- Described as a study physician at the NRZ-TSE in the 2020 Emerging Infectious Diseases paper on physicians among sporadic CJD cases in Germany.
- Lead author of the August 2025 bulletin on investigating a possible CJD cluster in the Greater Stuttgart area.
- Co-author with Zerr, Mok and Mead of the February 2026 Lancet Neurology review of prion disease biomarkers.
- Co-author of the international guideline for CJD biomarkers and criteria.
Timeline
- 2020Physicians among CJD cases paper.
- 2025Cluster investigation bulletin.
- 2026Lancet Neurology review.
Institutions
Research papers
Works with
This page covers public professional work only. To correct it or ask for it to be removed, write to hello@thegenerativebrain.org.
Last checked 16 October 2026
Sources for this page
- Biomarkers and diagnostic guidelines for sporadic CJD (Hermann et al., Lancet Neurology 2021; author manuscript UCL)
- Concordance of CSF RT-QuIC across the European CJD Surveillance Network (Eur J Neurol 2022)
- Hermann et al., Sporadic Creutzfeldt-Jakob disease among physicians, Germany, 1993-2018 (Emerging Infectious Diseases 26(8), August 2020)
- Hermann et al., Investigation of a possible spatial-temporal cluster of CJD by the National Reference Center and public health services (Epidemiologisches Bulletin, 11 August 2025; Robert Koch Institute record)
- Lancet Neurology 2026: advances in biomarkers for diagnosis and prognosis of prion diseases (PubMed record)